ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,188.68
0.51%
Dow Jones
38,386.09
0.00%
Gold vs US Dollar
2,310.95
-0.97%
Brent Oil
87.635
0.40%
Bitcoin
61,307.63
-3.96%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Autolus Therapeutics PLC (AUTL)

  7. Autolus Therapeutics PLC (AUTL) News

Autolus Therapeutics (AUTL)

Autolus Therapeutics PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AUTL
DateTimeSourceHeadlineSymbolCompany
24/04/202415:00GlobeNewswire Inc.Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCONASDAQ:AUTLAutolus Therapeutics PLC
23/04/202412:00GlobeNewswire Inc.Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
02/04/202412:00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALLNASDAQ:AUTLAutolus Therapeutics PLC
01/04/202412:00GlobeNewswire Inc.Autolus Therapeutics Announces Changes to its Board of DirectorsNASDAQ:AUTLAutolus Therapeutics PLC
14/03/202411:00GlobeNewswire Inc.Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
12/03/202411:00GlobeNewswire Inc.Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing siteNASDAQ:AUTLAutolus Therapeutics PLC
11/03/202411:00GlobeNewswire Inc.Autolus Therapeutics announces publication in Blood Cancer JournalNASDAQ:AUTLAutolus Therapeutics PLC
29/02/202412:00GlobeNewswire Inc.Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
23/02/202422:28Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AUTLAutolus Therapeutics PLC
22/02/202412:00GlobeNewswire Inc.Autolus Therapeutics announces publication in Nature Communications NASDAQ:AUTLAutolus Therapeutics PLC
21/02/202422:01Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AUTLAutolus Therapeutics PLC
14/02/202413:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
09/02/202422:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AUTLAutolus Therapeutics PLC
08/02/202421:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202412:00GlobeNewswire Inc.Autolus Announces Pricing of Underwritten OfferingNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202411:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202410:45GlobeNewswire Inc.BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  NASDAQ:AUTLAutolus Therapeutics PLC
08/02/202403:00Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AUTLAutolus Therapeutics PLC
31/01/202421:10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
26/01/202418:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
23/01/202412:00GlobeNewswire Inc.Autolus Therapeutics announces publication in ACS Chemical BiologyNASDAQ:AUTLAutolus Therapeutics PLC
22/01/202412:54Dow Jones NewsAutolus Therapeutics Gets BLA Acceptance for Obecabtagene AutoleucelNASDAQ:AUTLAutolus Therapeutics PLC
22/01/202412:00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)NASDAQ:AUTLAutolus Therapeutics PLC
10/01/202420:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
10/01/202412:00GlobeNewswire Inc.Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of DirectorsNASDAQ:AUTLAutolus Therapeutics PLC
22/12/202313:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
22/12/202312:00GlobeNewswire Inc.Autolus Therapeutics Announces Changes to its Board of DirectorsNASDAQ:AUTLAutolus Therapeutics PLC
11/12/202313:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
10/12/202301:30GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023NASDAQ:AUTLAutolus Therapeutics PLC
28/11/202319:59Dow Jones NewsCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNASDAQ:AUTLAutolus Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:AUTL

Your Recent History

LSE
SOLG
Solgold
LSE
SYME
Supply@me Capital
LSE
MIN
Minoan
LSE
GGP
Greatland Gold
LSE
PFC
Petrofac
LSE
BOO
Boohoo
LSE
DELT
Deltic Energy
LSE
AAZ
Anglo Asian Mining
LSE
POS
Plexus
LSE
VAST
Vast Resources
LSE
TERN
Tern
LSE
CARD
Card Factory
LSE
TRP
Tower Resources
LSE
AXL
Arrow Exploration
LSE
AAU
Ariana Resources
LSE
IGR
Ig Design
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved